Table 6 Overview of dose recommendations and other advice for diagnostic radiopharmaceuticals
From: Safe use of radiopharmaceuticals in patients with chronic kidney disease: a systematic review
Radiopharmaceutical | Stage of kidney failure (CKD) | Dose recommendation | Other advice |
|---|---|---|---|
[18F]fludeoxyglucose | 1, 2, 3, 4 or 5 | No adjustment in dose or protocol is needed (Akers et al. 2016; Kode et al. 2017) | No adjustment in image time (Akers et al. 2016; Kode et al. 2017) |
| Â | Â | Dose adjustment should be based on the optimized radiation dose (Laffon et al. 2008) | The more severe the kidney failure, the later the imaging should be, without necessarily beginning the acquisition beyond 160Â min after injection (Laffon et al. 2008) |
| Â | Â | ND | No large impact on assessment of scan (Minamimoto et al. 2007) |
| Â | 5 | ND | The effect of elevated FDG uptake in the background organs or blood pool may influence interpretation of the image in patients with CKD on haemodialysis (Toriihara et al. 2015) |